Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HB002 M

Next Previous
Drug Profile

HB002 M

Alternative Names: HB-002-1M; HB-002.1; HB-002.1M; Recombinant human vascular endothelial growth factor receptor-immunoglobulin Fc fusion protein

Latest Information Update: 08 Apr 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Huabo Biopharm
  • Class Antineoplastics; Eye disorder therapies; Immunoglobulins; Recombinant fusion proteins
  • Mechanism of Action Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diabetic macular oedema; Wet age-related macular degeneration

Most Recent Events

  • 08 Apr 2022 Phase-II clinical trials in Diabetic macular oedema in China (Intravitreous)
  • 08 Apr 2022 Phase-II clinical trials in Wet age-related macular degeneration (In the elderly, In adults) in China (Intravitreous)
  • 25 Nov 2021 HB002 M is still in phase-I development in Wet age-related macular degeneration(In the elderly, In adults) in China (Intravitreous, Injection) (Huabo Biopharm, November 2021)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top